Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FANG vaccine |
Synonyms | |
Therapy Description |
Vigil (FANG vaccine) is a combination of autologous tumor cells expressing recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and RNAi against furin convertase. FANG stimulates cell maturation through GM-CSF and prevents GM-CSF degradation by Tgfb1 and Tgfb2 (PMID: 22186789). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FANG vaccine | Vigil|bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine | Vigil (FANG vaccine) is a combination of autologous tumor cells expressing recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and RNAi against furin convertase. FANG stimulates cell maturation through GM-CSF and prevents GM-CSF degradation by Tgfb1 and Tgfb2 (PMID: 22186789). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02574533 | Phase I | Pembrolizumab FANG vaccine | Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma | Completed | USA | 0 |
NCT02511132 | Phase II | FANG vaccine Docetaxel + Gemcitabine FANG vaccine + Irinotecan + Temozolomide | A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma | Completed | USA | 0 |
NCT03842865 | Expanded access | FANG vaccine | Expanded Access of Vigil in Solid Tumors | Temporarily not available | USA | 0 |
NCT02346747 | Phase II | FANG vaccine | Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL) | Active, not recruiting | USA | 0 |